조린거-엘리슨 증후군 치료 시장, 규모, 점유율, 동향, 산업 분석 보고서 : 치료별, 진단별, 최종 사용자별, 지역별 - 시장 예측(2024-2032년)

The global Zollinger-Ellison syndrome treatment market size is expected to reach USD 1,988.13 million by 2032, according to a new study by Polaris Market Research. The report "Zollinger-Ellison Syndrome Treatment Market Size, Share, Trends, Industry Analysis Report: By Treatment (Chemotherapy, Surgical Resection, and Others); Diagnosis; End Users (Hospitals, Specialty Clinics, and Others); and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast, 2024-2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The Zollinger-Ellison syndrome (ZES) treatment market is growing rapidly owing to increasing awareness of the disease, advancements in diagnostic technologies, and the development of targeted therapies. Key factors such as the rising prevalence of ZES, improvements in healthcare infrastructure, and the availability of novel treatments such as proton pump inhibitors and somatostatin analogs also drive the market growth.

Further, ongoing research into new drug formulations and combination therapies and expanding indications for existing medications are expected to offer lucrative opportunities for the market during the forecast period. Trends such as personalized medicine and the integration of digital health solutions are also expected to shape the market in the coming years. In addition, the market is poised for significant expansion, fueled by an increasing focus on improving patient outcomes and quality of life.

Zollinger-Ellison Syndrome Treatment Market Report Highlights

Based on treatment, the surgical resection segment dominates the market due to its potential for curative outcomes. However, the chemotherapy segment is experiencing the highest growth due to emerging drug therapies and combination treatments enhancing efficacy.

In terms of end users, the hospitals segment is leading the market, driven by their capacity to provide comprehensive care and advanced diagnostic technologies. On the other hand, the specialty clinics segment is showing the highest growth, reflecting an increasing focus on specialized and personalized treatment options.

North America is the dominant region, benefiting from advanced healthcare infrastructure and high adoption of innovative treatments. However, Asia Pacific has the highest-growing regional market, driven by increasing healthcare investments and rising patient awareness in emerging markets.

Polaris Market Research has segmented the Zollinger-Ellison syndrome treatment market report on the basis of treatment, end users, and region:

By Treatment Outlook (Revenue - USD Million, 2019-2032)

Chemotherapy

Surgical Resection

Others

By Diagnosis Outlook (Revenue - USD Million, 2019-2032)

Blood Test

CT scan Ultrasound

X-Ray

Others

By End Users Outlook (Revenue - USD Million, 2019-2032)

Hospitals

Specialty Clinics

Others

By Regional Outlook (Revenue - USD Million, 2019-2032)

North America

US

Canada

Europe

Germany

France

UK

Italy

Spain

Netherlands

Russia

Rest of Europe

Asia Pacific

China

Japan

India

Malaysia

South Korea

Indonesia

Australia

Vietnam

Rest of Asia Pacific

Middle East & Africa

Saudi Arabia

UAE

Israel

South Africa

Rest of Middle East & Africa

Latin America

Mexico

Brazil

Argentina

Rest of Latin America

Table of Contents

1. Introduction

• 1.1. Report Description
  • 1.1.1. Objectives of the Study
  • 1.1.2. Market Scope
  • 1.1.3. Assumptions
• 1.2. Stakeholders

2. Executive Summary

• 2.1. Market Highlights

3. Research Methodology

• 3.1. Overview
  • 3.1.1. Data Mining
• 3.2. Data Sources
  • 3.2.1. Primary Sources
  • 3.2.2. Secondary Sources

4. Global Zollinger-Ellison Syndrome Treatment Market Insights

• 4.1. Zollinger-Ellison Syndrome Treatment Market - Market Snapshot
• 4.2. Zollinger-Ellison Syndrome Treatment Market Dynamics
  • 4.2.1. Drivers and Opportunities
    • 4.2.1.1. Advancements in Diagnostic Technologies Are Driving Market Growth
    • 4.2.1.2. Increased Focus on Targeted Therapies is Propelling Market Size
  • 4.2.2. Restraints and Challenges
    • 4.2.2.1. Limited Awareness and Diagnosis Challenges in Zollinger-Ellison Syndrome
• 4.3. Porter's Five Forces Analysis
  • 4.3.1. Bargaining Power of Suppliers (Moderate)
  • 4.3.2. Threats of New Entrants: (Low)
  • 4.3.3. Bargaining Power of Buyers (Moderate)
  • 4.3.4. Threat of Substitute (Moderate)
  • 4.3.5. Rivalry among existing firms (High)
• 4.4. PESTEL Analysis
• 4.5. Zollinger-Ellison Syndrome Treatment Market Trends
• 4.6. Value Chain Analysis
• 4.7. COVID-19 Impact Analysis

5. Global Zollinger-Ellison Syndrome Treatment Market, by Treatment

• 5.1. Key Findings
• 5.2. Introduction
  • 5.2.1. Global Zollinger-Ellison Syndrome Treatment Market, by Treatment, 2019-2032 (USD million)
• 5.3. Chemotherapy
  • 5.3.1. Global Zollinger-Ellison Syndrome Treatment Market, by Chemotherapy, by Region, 2019-2032 (USD million)
• 5.4. Surgical Resection
  • 5.4.1. Global Zollinger-Ellison Syndrome Treatment Market, by Surgical Resection, by Region, 2019-2032 (USD million)
• 5.5. Others
  • 5.5.1. Global Zollinger-Ellison Syndrome Treatment Market, by Others, by Region, 2019-2032 (USD million)

6. Global Zollinger-Ellison Syndrome Treatment Market, by Diagnosis

• 6.1. Key Findings
• 6.2. Introduction
  • 6.2.1. Global Zollinger-Ellison Syndrome Treatment Market, by Diagnosis, 2019-2032 (USD million)
• 6.3. Blood Test
  • 6.3.1. Global Zollinger-Ellison Syndrome Treatment Market, by Blood Test, by Region, 2019-2032 (USD million)
• 6.4. CT scan Ultrasound
  • 6.4.1. Global Zollinger-Ellison Syndrome Treatment Market, by CT scan Ultrasound, by Region, 2019-2032 (USD million)
• 6.5. X-Ray
  • 6.5.1. Global Zollinger-Ellison Syndrome Treatment Market, by X-Ray, by Region, 2019-2032 (USD million)
• 6.6. Others
  • 6.6.1. Global Zollinger-Ellison Syndrome Treatment Market, by Others, by Region, 2019-2032 (USD million)

7. Global Zollinger-Ellison Syndrome Treatment Market, by End User

• 7.1. Key Findings
• 7.2. Introduction
  • 7.2.1. Global Zollinger-Ellison Syndrome Treatment Market, by End User, 2019-2032 (USD million)
• 7.3. Hospitals
  • 7.3.1. Global Zollinger-Ellison Syndrome Treatment Market, by Hospitals, by Region, 2019-2032 (USD million)
    • 7.3.1.1.
• 7.4. Speciality Clinics
  • 7.4.1. Global Zollinger-Ellison Syndrome Treatment Market, by Specialty Clinics, by Region, 2019-2032 (USD million)
• 7.5. Others
  • 7.5.1. Global Zollinger-Ellison Syndrome Treatment Market, by Others, by Region, 2019-2032 (USD million)

8. Global Zollinger-Ellison Syndrome Treatment Market, by Geography

• 8.1. Key Findings
• 8.2. Introduction
  • 8.2.1. Zollinger-Ellison Syndrome Treatment Market Assessment, By Geography, 2019-2032 (USD million)
• 8.3. Zollinger-Ellison Syndrome Treatment Market - North America
  • 8.3.1. North America: Zollinger-Ellison Syndrome Treatment Market, by Treatment, 2019-2032 (USD million)
  • 8.3.2. North America: Zollinger-Ellison Syndrome Treatment Market, by Diagnosis, 2019-2032 (USD million)
  • 8.3.3. North America: Zollinger-Ellison Syndrome Treatment Market, by End User, 2019-2032 (USD million)
  • 8.3.4. Zollinger-Ellison Syndrome Treatment Market - U.S.
    • 8.3.4.1. U.S.: Zollinger-Ellison Syndrome Treatment Market, by Treatment, 2019-2032 (USD million)
    • 8.3.4.2. U.S.: Zollinger-Ellison Syndrome Treatment Market, by Diagnosis, 2019-2032 (USD million)
    • 8.3.4.3. U.S.: Zollinger-Ellison Syndrome Treatment Market, by End User, 2019-2032 (USD million)
  • 8.3.5. Zollinger-Ellison Syndrome Treatment Market - Canada
    • 8.3.5.1. Canada: Zollinger-Ellison Syndrome Treatment Market, by Treatment, 2019-2032 (USD million)
    • 8.3.5.2. Canada: Zollinger-Ellison Syndrome Treatment Market, by Diagnosis, 2019-2032 (USD million)
    • 8.3.5.3. Canada: Zollinger-Ellison Syndrome Treatment Market, by End User, 2019-2032 (USD million)
• 8.4. Zollinger-Ellison Syndrome Treatment Market - Europe
  • 8.4.1. Europe: Zollinger-Ellison Syndrome Treatment Market, by Treatment, 2019-2032 (USD million)
  • 8.4.2. Europe: Zollinger-Ellison Syndrome Treatment Market, by Diagnosis, 2019-2032 (USD million)
  • 8.4.3. Europe: Zollinger-Ellison Syndrome Treatment Market, by End User, 2019-2032 (USD million)
  • 8.4.4. Zollinger-Ellison Syndrome Treatment Market - UK
    • 8.4.4.1. UK: Zollinger-Ellison Syndrome Treatment Market, by Treatment, 2019-2032 (USD million)
    • 8.4.4.2. UK: Zollinger-Ellison Syndrome Treatment Market, by Diagnosis, 2019-2032 (USD million)
    • 8.4.4.3. UK: Zollinger-Ellison Syndrome Treatment Market, by End User, 2019-2032 (USD million)
  • 8.4.5. Zollinger-Ellison Syndrome Treatment Market - France
    • 8.4.5.1. France: Zollinger-Ellison Syndrome Treatment Market, by Treatment, 2019-2032 (USD million)
    • 8.4.5.2. France: Zollinger-Ellison Syndrome Treatment Market, by Diagnosis, 2019-2032 (USD million)
    • 8.4.5.3. France: Zollinger-Ellison Syndrome Treatment Market, by End User, 2019-2032 (USD million)
  • 8.4.6. Zollinger-Ellison Syndrome Treatment Market - Germany
    • 8.4.6.1. Germany: Zollinger-Ellison Syndrome Treatment Market, by Treatment, 2019-2032 (USD million)
    • 8.4.6.2. Germany: Zollinger-Ellison Syndrome Treatment Market, by Diagnosis, 2019-2032 (USD million)
    • 8.4.6.3. Germany: Zollinger-Ellison Syndrome Treatment Market, by End User, 2019-2032 (USD million)
  • 8.4.7. Zollinger-Ellison Syndrome Treatment Market - Italy
    • 8.4.7.1. Italy: Zollinger-Ellison Syndrome Treatment Market, by Treatment, 2019-2032 (USD million)
    • 8.4.7.2. Italy: Zollinger-Ellison Syndrome Treatment Market, by Diagnosis, 2019-2032 (USD million)
    • 8.4.7.3. Italy: Zollinger-Ellison Syndrome Treatment Market, by End User, 2019-2032 (USD million)
  • 8.4.8. Zollinger-Ellison Syndrome Treatment Market - Spain
    • 8.4.8.1. Spain: Zollinger-Ellison Syndrome Treatment Market, by Treatment, 2019-2032 (USD million)
    • 8.4.8.2. Spain: Zollinger-Ellison Syndrome Treatment Market, by Diagnosis, 2019-2032 (USD million)
    • 8.4.8.3. Spain: Zollinger-Ellison Syndrome Treatment Market, by End User, 2019-2032 (USD million)
  • 8.4.9. Zollinger-Ellison Syndrome Treatment Market - Netherlands
    • 8.4.9.1. Netherlands: Zollinger-Ellison Syndrome Treatment Market, by Treatment, 2019-2032 (USD million)
    • 8.4.9.2. Netherlands: Zollinger-Ellison Syndrome Treatment Market, by Diagnosis, 2019-2032 (USD million)
    • 8.4.9.3. Netherlands: Zollinger-Ellison Syndrome Treatment Market, by End User, 2019-2032 (USD million)
  • 8.4.10. Zollinger-Ellison Syndrome Treatment Market - Russia
    • 8.4.10.1. Russia: Zollinger-Ellison Syndrome Treatment Market, by Treatment, 2019-2032 (USD million)
    • 8.4.10.2. Russia: Zollinger-Ellison Syndrome Treatment Market, by Diagnosis, 2019-2032 (USD million)
    • 8.4.10.3. Russia: Zollinger-Ellison Syndrome Treatment Market, by End User, 2019-2032 (USD million)
  • 8.4.11. Zollinger-Ellison Syndrome Treatment Market - Rest of Europe
    • 8.4.11.1. Rest of Europe: Zollinger-Ellison Syndrome Treatment Market, by Treatment, 2019-2032 (USD million)
    • 8.4.11.2. Rest of Europe: Zollinger-Ellison Syndrome Treatment Market, by Diagnosis, 2019-2032 (USD million)
    • 8.4.11.3. Rest of Europe: Zollinger-Ellison Syndrome Treatment Market, by End User, 2019-2032 (USD million)
• 8.5. Zollinger-Ellison Syndrome Treatment Market - Asia Pacific
  • 8.5.1. Asia Pacific: Zollinger-Ellison Syndrome Treatment Market, by Treatment, 2019-2032 (USD million)
  • 8.5.2. Asia Pacific: Zollinger-Ellison Syndrome Treatment Market, by Diagnosis, 2019-2032 (USD million)
  • 8.5.3. Asia Pacific: Zollinger-Ellison Syndrome Treatment Market, by End User, 2019-2032 (USD million)
  • 8.5.4. Zollinger-Ellison Syndrome Treatment Market - China
    • 8.5.4.1. China: Zollinger-Ellison Syndrome Treatment Market, by Treatment, 2019-2032 (USD million)
    • 8.5.4.2. China: Zollinger-Ellison Syndrome Treatment Market, by Diagnosis, 2019-2032 (USD million)
    • 8.5.4.3. China: Zollinger-Ellison Syndrome Treatment Market, by End User, 2019-2032 (USD million)
  • 8.5.5. Zollinger-Ellison Syndrome Treatment Market - India
    • 8.5.5.1. India: Zollinger-Ellison Syndrome Treatment Market, by Treatment, 2019-2032 (USD million)
    • 8.5.5.2. India: Zollinger-Ellison Syndrome Treatment Market, by Diagnosis, 2019-2032 (USD million)
    • 8.5.5.3. India: Zollinger-Ellison Syndrome Treatment Market, by End User, 2019-2032 (USD million)
  • 8.5.6. Zollinger-Ellison Syndrome Treatment Market - Malaysia
    • 8.5.6.1. Malaysia: Zollinger-Ellison Syndrome Treatment Market, by Treatment, 2019-2032 (USD million)
    • 8.5.6.2. Malaysia: Zollinger-Ellison Syndrome Treatment Market, by Diagnosis, 2019-2032 (USD million)
    • 8.5.6.3. Malaysia: Zollinger-Ellison Syndrome Treatment Market, by End User, 2019-2032 (USD million)
  • 8.5.7. Zollinger-Ellison Syndrome Treatment Market - Japan
    • 8.5.7.1. Japan: Zollinger-Ellison Syndrome Treatment Market, by Treatment, 2019-2032 (USD million)
    • 8.5.7.2. Japan: Zollinger-Ellison Syndrome Treatment Market, by Diagnosis, 2019-2032 (USD million)
    • 8.5.7.3. Japan: Zollinger-Ellison Syndrome Treatment Market, by End User, 2019-2032 (USD million)
  • 8.5.8. Zollinger-Ellison Syndrome Treatment Market - Indonesia
    • 8.5.8.1. Indonesia: Zollinger-Ellison Syndrome Treatment Market, by Treatment, 2019-2032 (USD million)
    • 8.5.8.2. Indonesia: Zollinger-Ellison Syndrome Treatment Market, by Diagnosis, 2019-2032 (USD million)
    • 8.5.8.3. Indonesia: Zollinger-Ellison Syndrome Treatment Market, by End User, 2019-2032 (USD million)
  • 8.5.9. Zollinger-Ellison Syndrome Treatment Market - South Korea
    • 8.5.9.1. South Korea: Zollinger-Ellison Syndrome Treatment Market, by Treatment, 2019-2032 (USD million)
    • 8.5.9.2. South Korea: Zollinger-Ellison Syndrome Treatment Market, by Diagnosis, 2019-2032 (USD million)
    • 8.5.9.3. South Korea: Zollinger-Ellison Syndrome Treatment Market, by End User, 2019-2032 (USD million)
  • 8.5.10. Zollinger-Ellison Syndrome Treatment Market - Australia
    • 8.5.10.1. Australia: Zollinger-Ellison Syndrome Treatment Market, by Treatment, 2019-2032 (USD million)
    • 8.5.10.2. Australia: Zollinger-Ellison Syndrome Treatment Market, by Diagnosis, 2019-2032 (USD million)
    • 8.5.10.3. Australia: Zollinger-Ellison Syndrome Treatment Market, by End User, 2019-2032 (USD million)
  • 8.5.11. Zollinger-Ellison Syndrome Treatment Market - Rest of Asia Pacific
    • 8.5.11.1. Rest of Asia Pacific: Zollinger-Ellison Syndrome Treatment Market, by Treatment, 2019-2032 (USD million)
    • 8.5.11.2. Rest of Asia Pacific: Zollinger-Ellison Syndrome Treatment Market, by Diagnosis, 2019-2032 (USD million)
    • 8.5.11.3. Rest of Asia Pacific: Zollinger-Ellison Syndrome Treatment Market, by End User, 2019-2032 (USD million)
• 8.6. Zollinger-Ellison Syndrome Treatment Market - Middle East & Africa
  • 8.6.1. Middle East & Africa: Zollinger-Ellison Syndrome Treatment Market, by Treatment, 2019-2032 (USD million)
  • 8.6.2. Middle East & Africa: Zollinger-Ellison Syndrome Treatment Market, by Diagnosis, 2019-2032 (USD million)
  • 8.6.3. Middle East & Africa: Zollinger-Ellison Syndrome Treatment Market, by End User, 2019-2032 (USD million)
  • 8.6.4. Zollinger-Ellison Syndrome Treatment Market - Saudi Arabia
    • 8.6.4.1. Saudi Arabia: Zollinger-Ellison Syndrome Treatment Market, by Treatment, 2019-2032 (USD million)
    • 8.6.4.2. Saudi Arabia: Zollinger-Ellison Syndrome Treatment Market, by Diagnosis, 2019-2032 (USD million)
    • 8.6.4.3. Saudi Arabia: Zollinger-Ellison Syndrome Treatment Market, by End User, 2019-2032 (USD million)
  • 8.6.5. Zollinger-Ellison Syndrome Treatment Market - UAE
    • 8.6.5.1. UAE: Zollinger-Ellison Syndrome Treatment Market, by Treatment, 2019-2032 (USD million)
    • 8.6.5.2. UAE: Zollinger-Ellison Syndrome Treatment Market, by Diagnosis, 2019-2032 (USD million)
    • 8.6.5.3. UAE: Zollinger-Ellison Syndrome Treatment Market, by End User, 2019-2032 (USD million)
  • 8.6.6. Zollinger-Ellison Syndrome Treatment Market - Israel
    • 8.6.6.1. Israel: Zollinger-Ellison Syndrome Treatment Market, by Treatment, 2019-2032 (USD million)
    • 8.6.6.2. Israel: Zollinger-Ellison Syndrome Treatment Market, by Diagnosis, 2019-2032 (USD million)
    • 8.6.6.3. Israel: Zollinger-Ellison Syndrome Treatment Market, by End User, 2019-2032 (USD million)
  • 8.6.7. Zollinger-Ellison Syndrome Treatment Market - South Africa
    • 8.6.7.1. South Africa: Zollinger-Ellison Syndrome Treatment Market, by Treatment, 2019-2032 (USD million)
    • 8.6.7.2. South Africa: Zollinger-Ellison Syndrome Treatment Market, by Diagnosis, 2019-2032 (USD million)
    • 8.6.7.3. South Africa: Zollinger-Ellison Syndrome Treatment Market, by End User, 2019-2032 (USD million)
  • 8.6.8. Zollinger-Ellison Syndrome Treatment Market - Rest of Middle East & Africa
    • 8.6.8.1. Rest of Middle East & Africa: Zollinger-Ellison Syndrome Treatment Market, by Treatment, 2019-2032 (USD million)
    • 8.6.8.2. Rest of Middle East & Africa: Zollinger-Ellison Syndrome Treatment Market, by Diagnosis, 2019-2032 (USD million)
    • 8.6.8.3. Rest of Middle East & Africa: Zollinger-Ellison Syndrome Treatment Market, by End User, 2019-2032 (USD million)
• 8.7. Zollinger-Ellison Syndrome Treatment Market - Latin America
  • 8.7.1. Latin America: Zollinger-Ellison Syndrome Treatment Market, by Treatment, 2019-2032 (USD million)
  • 8.7.2. Latin America: Zollinger-Ellison Syndrome Treatment Market, by Diagnosis, 2019-2032 (USD million)
  • 8.7.3. Latin America: Zollinger-Ellison Syndrome Treatment Market, by End User, 2019-2032 (USD million)
  • 8.7.4. Zollinger-Ellison Syndrome Treatment Market - Mexico
    • 8.7.4.1. Mexico: Zollinger-Ellison Syndrome Treatment Market, by Treatment, 2019-2032 (USD million)
    • 8.7.4.2. Mexico: Zollinger-Ellison Syndrome Treatment Market, by Diagnosis, 2019-2032 (USD million)
    • 8.7.4.3. Mexico: Zollinger-Ellison Syndrome Treatment Market, by End User, 2019-2032 (USD million)
  • 8.7.5. Zollinger-Ellison Syndrome Treatment Market - Brazil
    • 8.7.5.1. Brazil: Zollinger-Ellison Syndrome Treatment Market, by Treatment, 2019-2032 (USD million)
    • 8.7.5.2. Brazil: Zollinger-Ellison Syndrome Treatment Market, by Diagnosis, 2019-2032 (USD million)
    • 8.7.5.3. Brazil: Zollinger-Ellison Syndrome Treatment Market, by End User, 2019-2032 (USD million)
  • 8.7.6. Zollinger-Ellison Syndrome Treatment Market - Argentina
    • 8.7.6.1. Argentina: Zollinger-Ellison Syndrome Treatment Market, by Treatment, 2019-2032 (USD million)
    • 8.7.6.2. Argentina: Zollinger-Ellison Syndrome Treatment Market, by Diagnosis, 2019-2032 (USD million)
    • 8.7.6.3. Argentina: Zollinger-Ellison Syndrome Treatment Market, by End User, 2019-2032 (USD million)
  • 8.7.7. Zollinger-Ellison Syndrome Treatment Market - Rest of Latin America
    • 8.7.7.1. Rest of Latin America: Zollinger-Ellison Syndrome Treatment Market, by Treatment, 2019-2032 (USD million)
    • 8.7.7.2. Rest of Latin America: Zollinger-Ellison Syndrome Treatment Market, by Diagnosis, 2019-2032 (USD million)
    • 8.7.7.3. Rest of Latin America: Zollinger-Ellison Syndrome Treatment Market, by End User, 2019-2032 (USD million)

9. Competitive Landscape

• 9.1. Expansion and Acquisition Analysis
  • 9.1.1. Expansion
  • 9.1.2. Acquisitions
• 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

• 10.1. Pfizer Inc.
  • 10.1.1. Company Overview
  • 10.1.2. Financial Performance
  • 10.1.3. Product Benchmarking
  • 10.1.4. Recent Development
• 10.2. Takeda Pharmaceutical Company Limited
  • 10.2.1. Company Overview
  • 10.2.2. Financial Performance
  • 10.2.3. Product Benchmarking
  • 10.2.4. Recent Development
• 10.3. Novartis AG
  • 10.3.1. Company Overview
  • 10.3.2. Financial Performance
  • 10.3.3. Product Benchmarking
  • 10.3.4. Recent Development
• 10.4. Boehringer Ingelheim International GmbH
  • 10.4.1. Company Overview
  • 10.4.2. Financial Performance
  • 10.4.3. Product Benchmarking
  • 10.4.4. Recent Development
• 10.5. AstraZeneca plc
  • 10.5.1. Company Overview
  • 10.5.2. Financial Performance
  • 10.5.3. Product Benchmarking
  • 10.5.4. Recent Development
• 10.6. GlaxoSmithKline plc
  • 10.6.1. Company Overview
  • 10.6.2. Financial Performance
  • 10.6.3. Product Benchmarking
  • 10.6.4. Recent Development
• 10.7. Eli Lilly and Company
  • 10.7.1. Company Overview
  • 10.7.2. Financial Performance
  • 10.7.3. Product Benchmarking
  • 10.7.4. Recent Development
• 10.8. Sanofi S.A.
  • 10.8.1. Company Overview
  • 10.8.2. Financial Performance
  • 10.8.3. Product Benchmarking
  • 10.8.4. Recent Development
• 10.9. AbbVie Inc.
  • 10.9.1. Company Overview
  • 10.9.2. Financial Performance
  • 10.9.3. Product Benchmarking
  • 10.9.4. Recent Development
• 10.10. Merck & Co., Inc.
  • 10.10.1. Company Overview
  • 10.10.2. Financial Performance
  • 10.10.3. Product Benchmarking
  • 10.10.4. Recent Development
• 10.11. Teva Pharmaceutical Industries Ltd.
  • 10.11.1. Company Overview
  • 10.11.2. Financial Performance
  • 10.11.3. Product Benchmarking
  • 10.11.4. Recent Development
• 10.12. Sun Pharmaceutical Industries Ltd.
  • 10.12.1. Company Overview
  • 10.12.2. Financial Performance
  • 10.12.3. Product Benchmarking
  • 10.12.4. Recent Development
• 10.13. Mylan N.V.
  • 10.13.1. Company Overview
  • 10.13.2. Financial Performance
  • 10.13.3. Product Benchmarking
  • 10.13.4. Recent Development
• 10.14. Hoffmann-La Roche Ltd.
  • 10.14.1. Company Overview
  • 10.14.2. Financial Performance
  • 10.14.3. Product Benchmarking
  • 10.14.4. Recent Development
• 10.15. Bristol-Myers Squibb Company
  • 10.15.1. Company Overview
  • 10.15.2. Financial Performance
  • 10.15.3. Product Benchmarking
  • 10.15.4. Recent Development